AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02607982 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
Study NCT04224064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
Study NCT03354364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pea hull fiber
Description: Snacks containing 15 g/day of ground pea hulls.
Study NCT03354364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Snacks without added fiber.
Study NCT03933475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality game
Description: Use of virtual reality games on television screens
Study NCT04569110 — intervention group
Intervention type: OTHER
Intervention: Not applicable. Observational study. Retrospective analysis of samples.
Description: Not applicable. Observational study. Retrospective analysis of samples.
Study NCT03362463 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT02733809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
Study NCT02103621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Study NCT02103621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taper and Monitoring (TAP-M)
Study NCT02609880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
Study NCT02609880 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
Study NCT03147235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vitrectomy with music listening
Description: Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
Study NCT04000867 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Magnetic Stimulation (TCMS)
Description: The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
Study NCT04000867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Magnetic Stimulation (TCMS)
Description: The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
Study NCT04876794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABLE Exoskeleton
Description: Participants with SCI will undergo a training programme with the ABLE Exoskeleton device three times a week for four to six weeks for a total of 12 sessions.
Study NCT01599390 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted.
Study NCT00403897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 3350 Na bicarbonate NaCl KCl
Description: 6.9g sachet, oral
Study NCT04378322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and food purchasing tool + telenutrition
Description: Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks) and schedule appointments with a registered dietitian.
Study NCT04378322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and food purchasing tool
Description: Participants will be asked to use a meal planning and food purchasing feature regularly (at least once every two weeks).
Study NCT04378322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education tool
Description: Participants will be asked to review nutrition education materials online.
Study NCT01360541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation
Description: HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
Study NCT01360541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surveillance
Description: Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
Study NCT02331797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Technique
Description: Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
Study NCT02331797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscopic Technique
Description: Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
Study NCT03115294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: iv injection
Study NCT03486158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CalproSmart™ system
Description: Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
Study NCT00835224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NAME
Description: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
Study NCT00835224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: To treat low blood pressure.
Study NCT00835224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill with an inactive substance that looks like the study drug.
Study NCT00803790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium+vitamin D combination
Description: A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
Study NCT03115294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilator positive end expiratory pressure adjustment
Description: Positive end-expiratory pressure variation
Study NCT03115294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videorecording
Description: Myocardial movement videorecording
Study NCT01000623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine
Description: Given orally
Study NCT01000623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: Given orally
Study NCT03950596 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA and RNA test
Description: DNA and RNA tests will be sent to a genetic laboratory for analysis
Study NCT01000623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01000623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypnotherapy
Description: Practice hypnosis
Study NCT01000623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypnotherapy
Description: Practice hypnosis
Study NCT01000623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mind-body intervention procedure
Description: Practice focused attention
Study NCT01242748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
Study NCT01242748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
Study NCT01827826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic intervention to prevent Diabetes Mellitus, Type 2
Description: Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
Study NCT00803790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: alendronate
Description: A single dose tablet of 70mg alendronate in one treatment period of each sequence.
Study NCT00803790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: Vitamin D
Description: Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
Study NCT03231202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.
Study NCT01932710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White Blood Cell Transfusion
Description: Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
Study NCT02789683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine emulsion
Description: Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
Study NCT02789683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coarse emulsion
Description: Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
Study NCT02789683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
Study NCT04357288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: The Patient Decision Aid (PDA) is an interactive website designed for use by a participant without the need of their clinician present. It provides information about the atrial fibrillation diagnosis, possible treatments, the effect of this diagnosis on daily life, and how to prepare for a discussion about medications with a clinician. Participants may interact with the website by inputting their health information into the stroke risk calculator or answering questions about their values, goals, thoughts, etc. that they would like to discuss with their clinician.
Study NCT02787824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose Supplement
Study NCT02787824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose Supplement
Study NCT01725581 — intervention group
Intervention type: PROCEDURE
Intervention: Observed Structured Assessment Tool in Pelvic Examination
Description: Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
Study NCT04357288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encounter Decision Aid
Description: The Encounter Decision Aid (EDA) is an interactive website designed for use by a participant and their clinician together. Together, the clinician and participant can go through the website together and input the participant's health information into the same stroke risk calculator also in the PDA. The EDA also provides information about the diagnosis of AF, living with this diagnosis, and possible treatments, and prompts discussion of how a participant's values affects these aspects of AF.
Study NCT01900600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
Study NCT01900600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary exercise test
Description: All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
Study NCT01900600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
Study NCT01900600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiogram
Description: An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
Study NCT04206319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: an alpha particle-emitting drug, dose consists of 55 kBq/kg (1.49 microcurie/kg); administered every 4 days
Study NCT04206319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F Sodium Fluoride
Description: 18F-NaF (Sodium Fluoride) is a radio-pharmaceutical used to image skeletal pathology with positron emission tomography (PET) imaging
Study NCT03025789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
Study NCT00699439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based asthma flow diagram
Description: If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
Study NCT00514943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: experimental drug taken once daily orally
Study NCT00514943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: active comparator administered weekly intravenously
Study NCT03559088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine App
Description: Smart phone app used to report migraine burden to the EHR.
Study NCT01875354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplements and TR90 Eating Plan
Description: Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
Study NCT01875354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Low Fat Eating Plan
Study NCT03950596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
Study NCT03950596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Core Biopsy
Description: Core Biopsy will be taken from the quadriceps femoris muscle
Study NCT03876574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intra-arterially for 30 minutes
Study NCT03876574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given intra-arterially continuously for 14 days
Study NCT03876574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intra-arterially continuously with 5-FUDR
Study NCT05468164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT05468164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study NCT00792974 — intervention group
Intervention type: BEHAVIORAL
Intervention: A brief psycho-educational intervention
Description: A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment.
Study NCT02362477 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy in-person
Description: Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
Study NCT02362477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy through videoteleconference
Description: Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
Study NCT03866850 — intervention group
Intervention type: BEHAVIORAL
Intervention: Phase duration
Description: We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.